Skip to main content
Erschienen in: Obesity Surgery 1/2010

01.01.2010 | Clinical Research

Overexpression of 11β-Hydroxysteroid Dehydrogenase Type 1 in Hepatic and Visceral Adipose Tissue is Associated with Metabolic Disorders in Morbidly Obese Patients

verfasst von: René Baudrand, Cristian A. Carvajal, Arnoldo Riquelme, Mauricio Morales, Nancy Solis, Margarita Pizarro, Alex Escalona, Camilo Boza, Gustavo Pérez, Angélica Domínguez, Marco Arrese, Carlos E. Fardella

Erschienen in: Obesity Surgery | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

The enzyme 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) catalyzes intracellular glucocorticoid reactivation by conversion of cortisone to cortisol in different tissues and have been implicated in several metabolic disorders associated with obesity. The aim of this study was to evaluate the 11β-HSD1 expression in liver, visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) in morbidly obese patients undergoing bariatric surgery and its correlations with clinical, anthropometric, and biochemical variables.

Methods

A prospective study was conducted over a 27-month period. Hepatic, VAT, and SAT samples were obtained at the time of surgery. 11β-HSD1 and 18S gene expression was measured using real-time quantitative reverse transcriptase-polymerase chain reaction.

Results

Forty nine patients met the inclusion criteria [mean age: 42.2 ± 10 years, body mass index (BMI): 42 ± 6 kg/m2, 71% women and 63% with metabolic syndrome (MS)]. 11β-HSD1 mRNA levels were higher in liver than fat tissue (p < 0.001), being higher in SAT than in VAT (p < 0.001) without gender-specific differences. Hepatic expression of 11β-HSD1 correlated positively with SAT and VAT, alanine aminotransferase (ALT), and serum glucose and was inversely associated with BMI. 11β-HSD1 mRNA in VAT correlated positively with insulinemia, ALT, and LDL cholesterol. There were no associations between 11β-HSD1 mRNA in SAT and the variables analyzed.

Conclusions

11β-HSD1 expression is higher in liver in comparison to adipose tissue in obese patients. The observed correlations between hepatic and VAT 11β-HSD1 expression with dyslipidemia and insulin resistance suggest that this enzyme might have a pathogenic role in obesity and related metabolic disorders.
Literatur
1.
Zurück zum Zitat Reaven GM. Banting lecture. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–607.CrossRefPubMed Reaven GM. Banting lecture. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–607.CrossRefPubMed
2.
Zurück zum Zitat Dandona P, Aljada A, Chaudhuri A, et al. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111:1448–54.CrossRefPubMed Dandona P, Aljada A, Chaudhuri A, et al. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111:1448–54.CrossRefPubMed
3.
Zurück zum Zitat Tataranni PA. Metabolic syndrome: is there a pathophysiological common denominator? World Rev Nutr Diet. 2005;94:75–83.CrossRefPubMed Tataranni PA. Metabolic syndrome: is there a pathophysiological common denominator? World Rev Nutr Diet. 2005;94:75–83.CrossRefPubMed
4.
Zurück zum Zitat National Cholesterol Education Program. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.CrossRef National Cholesterol Education Program. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.CrossRef
5.
Zurück zum Zitat Alberti KG, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23:469–80.CrossRefPubMed Alberti KG, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23:469–80.CrossRefPubMed
6.
Zurück zum Zitat Gholam PM, Flancbaum L, Machan JT, et al. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol. 2007;102:399–408.CrossRefPubMed Gholam PM, Flancbaum L, Machan JT, et al. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol. 2007;102:399–408.CrossRefPubMed
7.
Zurück zum Zitat Salgado Junior W, Santos JS, Sankarankutty AK, et al. Nonalcoholic fatty liver disease and obesity. Acta Cir Bras. 2006;21(Suppl 1):72–8.PubMed Salgado Junior W, Santos JS, Sankarankutty AK, et al. Nonalcoholic fatty liver disease and obesity. Acta Cir Bras. 2006;21(Suppl 1):72–8.PubMed
8.
Zurück zum Zitat Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect “Cushing's disease of the omentum”? Lancet. 1997;349:1210–3.CrossRefPubMed Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect “Cushing's disease of the omentum”? Lancet. 1997;349:1210–3.CrossRefPubMed
9.
Zurück zum Zitat Siminialayi IM, Emem-Chioma PC. Glucocorticoids and the insulin resistance syndrome. Niger J Med. 2004;13:330–5.PubMed Siminialayi IM, Emem-Chioma PC. Glucocorticoids and the insulin resistance syndrome. Niger J Med. 2004;13:330–5.PubMed
10.
Zurück zum Zitat Krozowski Z, Li KX, Koyama K, et al. The type I and type II 11beta-hydroxysteroid dehydrogenase enzymes. J Steroid Biochem Mol Biol. 1999;69:391–401.CrossRefPubMed Krozowski Z, Li KX, Koyama K, et al. The type I and type II 11beta-hydroxysteroid dehydrogenase enzymes. J Steroid Biochem Mol Biol. 1999;69:391–401.CrossRefPubMed
11.
Zurück zum Zitat Ricketts ML, Verhaeg JM, Bujalska I, et al. Immunohistochemical localization of type 1 11beta-hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol Metab. 1998;83:1325–35.CrossRefPubMed Ricketts ML, Verhaeg JM, Bujalska I, et al. Immunohistochemical localization of type 1 11beta-hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol Metab. 1998;83:1325–35.CrossRefPubMed
12.
Zurück zum Zitat Tomlinson JW, Walker EA, Bujalska IJ, et al. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev. 2004;25:831–66.CrossRefPubMed Tomlinson JW, Walker EA, Bujalska IJ, et al. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev. 2004;25:831–66.CrossRefPubMed
13.
Zurück zum Zitat Bujalska IJ, Walker EA, Tomlinson JW, et al. 11Beta-hydroxysteroid dehydrogenase type 1 in differentiating omental human preadipocytes: from de-activation to generation of cortisol. Endocr Res. 2002;28:449–61.CrossRefPubMed Bujalska IJ, Walker EA, Tomlinson JW, et al. 11Beta-hydroxysteroid dehydrogenase type 1 in differentiating omental human preadipocytes: from de-activation to generation of cortisol. Endocr Res. 2002;28:449–61.CrossRefPubMed
14.
Zurück zum Zitat Atanasov AG, Nashev LG, Schweizer RA. et al Hexose-6-phosphate dehydrogenase determines the reaction direction of 11beta-hydroxysteroid dehydrogenase type 1 as an oxoreductase. FEBS Lett. 2004;571:129–33.CrossRefPubMed Atanasov AG, Nashev LG, Schweizer RA. et al Hexose-6-phosphate dehydrogenase determines the reaction direction of 11beta-hydroxysteroid dehydrogenase type 1 as an oxoreductase. FEBS Lett. 2004;571:129–33.CrossRefPubMed
15.
Zurück zum Zitat Freeman L, Hewison M, Hughes SV, et al. Expression of 11beta-hydroxysteroid dehydrogenase type 1 permits regulation of glucocorticoid bioavailability by human dendritic cells. Blood. 2005;106:2042–9.CrossRefPubMed Freeman L, Hewison M, Hughes SV, et al. Expression of 11beta-hydroxysteroid dehydrogenase type 1 permits regulation of glucocorticoid bioavailability by human dendritic cells. Blood. 2005;106:2042–9.CrossRefPubMed
16.
Zurück zum Zitat Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001;294:2166–70.CrossRefPubMed Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001;294:2166–70.CrossRefPubMed
17.
Zurück zum Zitat Paterson JM, Morton NM, Fievet C, et al. Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci U S A. 2004;101:7088–93.CrossRefPubMed Paterson JM, Morton NM, Fievet C, et al. Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci U S A. 2004;101:7088–93.CrossRefPubMed
18.
Zurück zum Zitat Morton NM, Paterson JM, Masuzaki H, et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes. 2004;53:931–8.CrossRefPubMed Morton NM, Paterson JM, Masuzaki H, et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes. 2004;53:931–8.CrossRefPubMed
19.
Zurück zum Zitat Alberti L, Girola A, Gilardini L, et al. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects. Int J Obes (Lond). 2007;31:1826–31.CrossRef Alberti L, Girola A, Gilardini L, et al. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects. Int J Obes (Lond). 2007;31:1826–31.CrossRef
20.
Zurück zum Zitat Paulsen SK, Pedersen SB, Fisker S, et al. 11Beta-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization. Obesity (Silver Spring). 2007;15:1954–60.CrossRef Paulsen SK, Pedersen SB, Fisker S, et al. 11Beta-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization. Obesity (Silver Spring). 2007;15:1954–60.CrossRef
21.
Zurück zum Zitat Walker BR, Andrew R. Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease. Ann N Y Acad Sci. 2006;1083:165–84.CrossRefPubMed Walker BR, Andrew R. Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease. Ann N Y Acad Sci. 2006;1083:165–84.CrossRefPubMed
22.
Zurück zum Zitat Valsamakis G, Anwar A, Tomlinson JW, et al. 11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2004;89:4755–61.CrossRefPubMed Valsamakis G, Anwar A, Tomlinson JW, et al. 11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2004;89:4755–61.CrossRefPubMed
23.
Zurück zum Zitat Berthiaume M, Laplante M, Festuccia WT, et al. 11beta-HSD1 inhibition improves triglyceridemia through reduced liver VLDL secretion and partitions lipids toward oxidative tissues. Am J Physiol Endocrinol Metab. 2007;293:E1045–52.CrossRefPubMed Berthiaume M, Laplante M, Festuccia WT, et al. 11beta-HSD1 inhibition improves triglyceridemia through reduced liver VLDL secretion and partitions lipids toward oxidative tissues. Am J Physiol Endocrinol Metab. 2007;293:E1045–52.CrossRefPubMed
24.
Zurück zum Zitat Atanasov AG, Odermatt A. Readjusting the glucocorticoid balance: an opportunity for modulators of 11beta-hydroxysteroid dehydrogenase type 1 activity? Endocr Metab Immune Disord Drug Targets. 2007;7:125–40.CrossRefPubMed Atanasov AG, Odermatt A. Readjusting the glucocorticoid balance: an opportunity for modulators of 11beta-hydroxysteroid dehydrogenase type 1 activity? Endocr Metab Immune Disord Drug Targets. 2007;7:125–40.CrossRefPubMed
25.
Zurück zum Zitat Tomlinson JW, Bujalska I, Stewart PM, et al. The role of 11 beta-hydroxysteroid dehydrogenase in central obesity and osteoporosis. Endocr Res. 2000;26:711–22.CrossRefPubMed Tomlinson JW, Bujalska I, Stewart PM, et al. The role of 11 beta-hydroxysteroid dehydrogenase in central obesity and osteoporosis. Endocr Res. 2000;26:711–22.CrossRefPubMed
26.
Zurück zum Zitat Mariniello B, Ronconi V, Rilli S, et al. Adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome. Eur J Endocrinol. 2006;155:435–41.CrossRefPubMed Mariniello B, Ronconi V, Rilli S, et al. Adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome. Eur J Endocrinol. 2006;155:435–41.CrossRefPubMed
27.
Zurück zum Zitat Desbriere R, Vuaroqueaux V, Achard V, et al. 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring). 2006;14:794–8.CrossRef Desbriere R, Vuaroqueaux V, Achard V, et al. 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring). 2006;14:794–8.CrossRef
28.
Zurück zum Zitat Basu R, Singh RJ, Basu A, et al. Splanchnic cortisol production occurs in humans: evidence for conversion of cortisone to cortisol via the 11-beta hydroxysteroid dehydrogenase (11beta-hsd) type 1 pathway. Diabetes. 2004;53:2051–9.CrossRefPubMed Basu R, Singh RJ, Basu A, et al. Splanchnic cortisol production occurs in humans: evidence for conversion of cortisone to cortisol via the 11-beta hydroxysteroid dehydrogenase (11beta-hsd) type 1 pathway. Diabetes. 2004;53:2051–9.CrossRefPubMed
29.
Zurück zum Zitat Munoz R, Carvajal C, Escalona A, et al. 11beta-Hydroxysteroid Dehydrogenase Type 1 is Overexpressed in Subcutaneous Adipose Tissue of Morbidly Obese Patients. Obes Surg. 2009;19:764–70.CrossRefPubMed Munoz R, Carvajal C, Escalona A, et al. 11beta-Hydroxysteroid Dehydrogenase Type 1 is Overexpressed in Subcutaneous Adipose Tissue of Morbidly Obese Patients. Obes Surg. 2009;19:764–70.CrossRefPubMed
30.
Zurück zum Zitat Carrasco F, Klaassen J, Papapietro K, et al. A proposal of guidelines for surgical management of obesity. Rev Med Chil. 2005;133:699–706.PubMed Carrasco F, Klaassen J, Papapietro K, et al. A proposal of guidelines for surgical management of obesity. Rev Med Chil. 2005;133:699–706.PubMed
31.
Zurück zum Zitat Acosta AM, Escalona M, Miz A, et al. Determination of the insulin resistance index by the Homeostasis Model Assessment in a population of Metropolitan Region in Chile. Rev Med Chil. 2002;130(11):1227–31.PubMed Acosta AM, Escalona M, Miz A, et al. Determination of the insulin resistance index by the Homeostasis Model Assessment in a population of Metropolitan Region in Chile. Rev Med Chil. 2002;130(11):1227–31.PubMed
32.
Zurück zum Zitat Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–52.CrossRefPubMed Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–52.CrossRefPubMed
33.
Zurück zum Zitat Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.CrossRefPubMed Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.CrossRefPubMed
34.
Zurück zum Zitat Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45.CrossRefPubMed Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45.CrossRefPubMed
35.
Zurück zum Zitat Altuna ME, Lelli SM, de Viale San Martin LC, et al. Effect of stress on hepatic 11beta-hydroxysteroid dehydrogenase activity and its influence on carbohydrate metabolism. Can J Physiol Pharmacol. 2006;84:977–84.CrossRefPubMed Altuna ME, Lelli SM, de Viale San Martin LC, et al. Effect of stress on hepatic 11beta-hydroxysteroid dehydrogenase activity and its influence on carbohydrate metabolism. Can J Physiol Pharmacol. 2006;84:977–84.CrossRefPubMed
36.
Zurück zum Zitat Holmes MC, Kotelevtsev Y, Mullins JJ, et al. Phenotypic analysis of mice bearing targeted deletions of 11beta-hydroxysteroid dehydrogenases 1 and 2 genes. Mol Cell Endocrinol. 2001;171:15–20.CrossRefPubMed Holmes MC, Kotelevtsev Y, Mullins JJ, et al. Phenotypic analysis of mice bearing targeted deletions of 11beta-hydroxysteroid dehydrogenases 1 and 2 genes. Mol Cell Endocrinol. 2001;171:15–20.CrossRefPubMed
37.
Zurück zum Zitat Seckl JR, Morton NM, Chapman KE, et al. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue. Recent Prog Horm Res. 2004;59:359–93.CrossRefPubMed Seckl JR, Morton NM, Chapman KE, et al. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue. Recent Prog Horm Res. 2004;59:359–93.CrossRefPubMed
38.
Zurück zum Zitat Walker EA, Stewart PM. 11beta-hydroxysteroid dehydrogenase: unexpected connections. Trends Endocrinol Metab. 2003;14:334–9.CrossRefPubMed Walker EA, Stewart PM. 11beta-hydroxysteroid dehydrogenase: unexpected connections. Trends Endocrinol Metab. 2003;14:334–9.CrossRefPubMed
39.
Zurück zum Zitat Boza C, Riquelme A, Ibanez L, et al. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg. 2005;15:1148–53.CrossRefPubMed Boza C, Riquelme A, Ibanez L, et al. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg. 2005;15:1148–53.CrossRefPubMed
40.
Zurück zum Zitat Paterson JM, Seckl JR, Mullins JJ. Genetic manipulation of 11beta-hydroxysteroid dehydrogenases in mice. Am J Physiol Regul Integr Comp Physiol. 2005;289:R642–52.PubMed Paterson JM, Seckl JR, Mullins JJ. Genetic manipulation of 11beta-hydroxysteroid dehydrogenases in mice. Am J Physiol Regul Integr Comp Physiol. 2005;289:R642–52.PubMed
41.
Zurück zum Zitat Liew PL, Lee WJ, Lee YC, et al. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease. Obes Surg. 2006;16:1584–93.CrossRefPubMed Liew PL, Lee WJ, Lee YC, et al. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease. Obes Surg. 2006;16:1584–93.CrossRefPubMed
42.
Zurück zum Zitat Arun J, Clements RH, Lazenby AJ, et al. The prevalence of nonalcoholic steatohepatitis is greater in morbidly obese men compared to women. Obes Surg. 2006;16:1351–8.CrossRefPubMed Arun J, Clements RH, Lazenby AJ, et al. The prevalence of nonalcoholic steatohepatitis is greater in morbidly obese men compared to women. Obes Surg. 2006;16:1351–8.CrossRefPubMed
43.
Zurück zum Zitat Andrews RC, Rooyackers O, Walker BR. Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab. 2003;88:285–91.CrossRefPubMed Andrews RC, Rooyackers O, Walker BR. Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab. 2003;88:285–91.CrossRefPubMed
44.
Zurück zum Zitat Kannisto K, Pietilainen KH, Ehrenborg E, et al. Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. J Clin Endocrinol Metab. 2004;89:4414–21.CrossRefPubMed Kannisto K, Pietilainen KH, Ehrenborg E, et al. Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. J Clin Endocrinol Metab. 2004;89:4414–21.CrossRefPubMed
45.
Zurück zum Zitat Hughes KA, Webster SP, Walker BR. 11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity. Expert Opin Investig Drugs. 2008;17:481–96.CrossRefPubMed Hughes KA, Webster SP, Walker BR. 11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity. Expert Opin Investig Drugs. 2008;17:481–96.CrossRefPubMed
46.
Zurück zum Zitat Friedman TC, Mastorakos G, Newman TD, et al. Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome X and NIDDM. Endocr J. 1996;43:645–55.CrossRefPubMed Friedman TC, Mastorakos G, Newman TD, et al. Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome X and NIDDM. Endocr J. 1996;43:645–55.CrossRefPubMed
47.
Zurück zum Zitat Jezkova J, Marek J, Prazny M, et al. Effect of hypercortisolism on development of atherosclerotic changes in blood vessels. Vnitr Lek. 2003;49:656–67.PubMed Jezkova J, Marek J, Prazny M, et al. Effect of hypercortisolism on development of atherosclerotic changes in blood vessels. Vnitr Lek. 2003;49:656–67.PubMed
48.
Zurück zum Zitat Yoshida C, Miyachi Y. Lipid metabolism in Cushing's syndrome. Nippon Rinsho. 2001;59(Suppl 3):177–80.PubMed Yoshida C, Miyachi Y. Lipid metabolism in Cushing's syndrome. Nippon Rinsho. 2001;59(Suppl 3):177–80.PubMed
49.
Zurück zum Zitat Nuotio-Antar AM, Hachey DL, Hasty AH. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice. Am J Physiol Endocrinol Metab. 2007;293:E1517–28.CrossRefPubMed Nuotio-Antar AM, Hachey DL, Hasty AH. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice. Am J Physiol Endocrinol Metab. 2007;293:E1517–28.CrossRefPubMed
50.
Zurück zum Zitat Wolf G. Glucocorticoids in adipocytes stimulate visceral obesity. Nutr Rev. 2002;60:148–51.CrossRefPubMed Wolf G. Glucocorticoids in adipocytes stimulate visceral obesity. Nutr Rev. 2002;60:148–51.CrossRefPubMed
51.
Zurück zum Zitat Wake DJ, Rask E, Livingstone DE, et al. Local and systemic impact of transcriptional up-regulation of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J Clin Endocrinol Metab. 2003;88:3983–8.CrossRefPubMed Wake DJ, Rask E, Livingstone DE, et al. Local and systemic impact of transcriptional up-regulation of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J Clin Endocrinol Metab. 2003;88:3983–8.CrossRefPubMed
52.
Zurück zum Zitat Turpeinen U, Markkanen H, Sane T, et al. Determination of free tetrahydrocortisol and tetrahydrocortisone ratio in urine by liquid chromatography-tandem mass spectrometry. Scand J Clin Lab Invest. 2006;66:147–59.CrossRefPubMed Turpeinen U, Markkanen H, Sane T, et al. Determination of free tetrahydrocortisol and tetrahydrocortisone ratio in urine by liquid chromatography-tandem mass spectrometry. Scand J Clin Lab Invest. 2006;66:147–59.CrossRefPubMed
Metadaten
Titel
Overexpression of 11β-Hydroxysteroid Dehydrogenase Type 1 in Hepatic and Visceral Adipose Tissue is Associated with Metabolic Disorders in Morbidly Obese Patients
verfasst von
René Baudrand
Cristian A. Carvajal
Arnoldo Riquelme
Mauricio Morales
Nancy Solis
Margarita Pizarro
Alex Escalona
Camilo Boza
Gustavo Pérez
Angélica Domínguez
Marco Arrese
Carlos E. Fardella
Publikationsdatum
01.01.2010
Verlag
Springer-Verlag
Erschienen in
Obesity Surgery / Ausgabe 1/2010
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-009-9937-0

Weitere Artikel der Ausgabe 1/2010

Obesity Surgery 1/2010 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.